Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

inical trials; reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and ... Stanley Global Healthcare Conference on Thursday, September 17, 2015. ... president of Lilly Oncology and Richard Gaynor , ... affairs for Lilly Oncology, will participate in a fireside ... A live audio webcast will be available on ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for ... 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed ... , Clinical trial sites can now use audio, video and interactivity to ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... the threats to themselves and relatives, study says , , FRIDAY, ... families in which some members have BRCA1 or 2 gene ... cancer -- typically avoid genetic counseling or testing, a new ... they,re less likely than women to pass on the information ...
... LOUIS, Feb. 27 Stereotaxis, Inc. (Nasdaq: ... Food and Drug Administration approved for marketing the NAVISTAR(R) ... Inc, a Johnson & Johnson company. The NAVISTAR(R) RMT ... Navigation System for mapping and radiofrequency (RF) ablation to ...
... N.J., Feb. 27 The Board of Directors of Schering-Plough ... dividend of 6.5 cents per common share. Payment will ... at the close of business on May 1, 2009. ... outstanding. The Board of Directors today also declared a quarterly ...
... of Long Term Care Workforce Put at Risk by FY ... LTC Sector to U.S. Economy, Jobs Base, Tax RevenueWASHINGTON, Feb. ... the nation,s long term care sector is a key driver ... revenue, state and national long term care leaders expressed alarm ...
... following is a statement by Robert Greenstein, Executive Director ... budget represents a bold and courageous proposal to make ... problems of our time -- a broken health care ... and other national needs.Particularly courageous are several proposals that ...
... FindingsNEWPORT NEWS, Va., Feb. 27 Women facing a ... the same or opposite breast with further testing using ... in the February 2009 "American Journal of Surgery." BSGI ... same or opposite breast in 10.9 percent of newly ...
Cached Medicine News:Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 2Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 3Health News:Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter 2Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 2Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 3Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 2Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 3Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 4Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 2Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 3
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
... Utilizing the most complex grinding ... accurate trial lens, are specifically ... quality and precision as the ... marco RT-300 refractor. Marco custom ...
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Medicine Products: